drugset / Trial / NCT04373031
Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer
Phase 2
Active not recruiting
12 enrolled
Providence Health & Services
Brooklyn ImmunoTherapeutics, LLC · collabMerck Sharp & Dohme LLC · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase II, randomized, open-label trial to evaluate the clinical and immunologic activity of pembrolizumab plus chemotherapy when combined with various immunotherapy induction regimens as neoadjuvant therapy for triple negative breast cancer (TNBC).
Timeline
- Start
- 2020-12-30
- Primary completion
- 2023-07-08
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IRX-2 | Protein / enzyme biologic | 1 ml | Subcutaneous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |